Render Target: SSR
Render Timestamp: 2024-11-14T22:21:29.911Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-20 06:23:28.709
Product last modified at: 2024-08-29T18:00:07.861Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

STF-083010 #92208

    Product Information

    Product Usage Information

    STF-083010 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.05 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 317.4 g/mol
    Purity >98%
    Molecular Formula C15H11NO3S2
    CAS 307543-71-1
    Solubility Soluble in DMSO at 30 mg/mL.

    Background

    In cells undergoing endoplasmic reticulum (ER) stress, the cell-permeable compound STF-083010 specifically inhibits inositol-requiring enzyme-1 (IRE1) RNase activity and blocks prolonged unfolded protein response (UPR) initiation. IRE1α-mediated splicing of X-box binding protein 1 (XBP1) mRNA induces expression of many UPR responsive genes. In a rat model of acute renal failure, STF-083010 treatment suppressed oxidative stress, inflammation, and apoptosis. These cellular changes coincided with reduced impairment of kidney structure and function. By inhibiting IRE1, STF-083010 prevented prolonged UPR and downregulated expression of GRP78, p-IRE1, XBP1s, CHOP, and caspase-3 (1). In a model of multiple myeloma xenografts under ER stress, STF-083010 inhibited IRE1 endonuclease activity and showed significant anti-myeloma activity (2). STF-083010 treatment in pancreatic cancer cell lines caused growth arrest at either the G1 or G2/M phases and induced apoptosis (3). Similar therapeutic results were seen as STF-083010 prevented thioacetamide-induced acute liver injury by reducing reactive oxygen species production and decreasing hepatic inflammation (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.